Switching to TASIGNA

There are a number of reasons why your doctor may decide it is time for you to switch from another medication to TASIGNA® (nilotinib) capsules to treat Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP):

  • Lack of response: Your body does not respond to treatment
  • Drug resistance: Over time, you lose your response to your medication. Your doctor may refer to this as drug resistance
  • Side effects: You experience side effects, such as diarrhea, nausea, vomiting, and severe muscle cramps
  • Drug intolerance: Your side effects become so bothersome they may keep you from taking your medication. Your doctor may determine that your body can no longer tolerate the side effects and switch you to TASIGNA

 

In a clinical trial, TASIGNA was shown to be effective among patients who had taken GLEEVEC® (imatinib mesylate) first and then switched to TASIGNA.

 

At the time of the study in the mid-2000s, major cytogenetic response (MCyR) was the measured response. Fifty-one percent of Ph+ CML patients (164 of 321 patients) in chronic phase achieved MCyR with TASIGNA. Later studies measured response using major molecular response (MMR) and DMR (MR4.5). 

 

Common side effects among those whose first treatment was GLEEVEC

In a clinical study, patients whose initial treatment for Ph+ CML-CP was GLEEVEC experienced certain common side effects more often than those whose first treatment was TASIGNA. For example, patients whose first treatment was GLEEVEC experienced more instances of:

  • Diarrhea
  • Nausea
  • Muscle spasms
  • Vomiting

 

Those on TASIGNA as their first treatment experienced more incidents of rash and headache compared to those starting on GLEEVEC.

 

Make your blood heard by speaking with your doctor

To have a productive conversation with your doctor about switching from your current medication to TASIGNA, download the Doctor Discussion Guide. You’ll find questions that you can discuss with your doctor to see if you may be resistant to, or intolerant of, your current treatment for Ph+ CML-CP.